Siemens Healthineers: Tax Clarity Unlocks the Spin-Off Door, But the Market Is Still Weighing the Odds
Published on 08/18/2026 at 05:41 | Redaktion boerse-global.de
The most consequential development for Siemens Healthineers this summer had nothing to do with scanners, imaging agents, or quarterly revenue. It was a tax ruling. In early August, Siemens AG confirmed that the relevant fiscal questions surrounding the planned separation of its medical technology arm had been resolved with the German tax authorities — a milestone that removes a significant layer of uncertainty from one of the most closely watched corporate restructurings in European healthcare.
Veronika Bienert, chief financial officer of the parent company, delivered the news personally. The clarification effectively green-lights the next phase of a process that could fundamentally reshape both the ownership structure and strategic direction of Healthineers. Yet the finish line remains distant: Jochen Schmitz, the CFO of Siemens Healthineers, has previously cautioned that creating the conditions for a sale of the Diagnostics division could take up to 24 months.
A Summer of Conflicting Signals
The tax breakthrough lands in the middle of a period when the company's financial narrative has grown increasingly nuanced. Late July saw management trim its growth expectations for fiscal 2026, guiding for comparable revenue growth of 3.5 to 4.0 percent — down from the earlier projection of 4.5 to 5.0 percent. In the same breath, however, the company raised its adjusted earnings-per-share forecast to a range of 2.35 to 2.45 euros.
The third quarter, which ended June 30, illustrated the tension between those two trajectories. Revenue came in at 5.76 billion euros, up 1.80 percent year over year, while EPS landed at 0.60 euros. The pattern suggests a business leaning harder into cost discipline as top-line momentum cools — a strategy that may appeal to margin-focused investors even as growth purists look elsewhere.
The Stock Tells Its Own Story
The market's response to this mixed picture has been characteristically volatile. On the most recent Monday, shares closed at 38.86 euros after a 2.0 percent decline, though another trading session saw the stock dip 2.3 percent to 38.76 euros. Over the trailing seven sessions, the cumulative loss stands at 1.8 percent — yet the 30-day view shows an 11 percent recovery, underscoring just how choppy the tape has become.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
The longer-term numbers remain sobering. The stock is down roughly 13 percent year to date, and sits about 22 percent below its 52-week high of 49.78 euros, set in late October. Berenberg, which downgraded the shares from Buy to Hold in early July and slashed its price target from 54 to 39 euros, did so before the tax clarity emerged — leaving its call as a snapshot of an earlier moment rather than a current verdict.
Buybacks as a Backstop
Management has not been passive in the face of the sell-off. Between June 1 and mid-August, the company repurchased 2,824,371 of its own shares on XETRA, including a tranche of 50,000 bought between August 10 and 16. The buyback program serves the dual purpose of supporting earnings per share arithmetically and signaling management's conviction that the equity is undervalued.
Thus far, however, the repurchases have not been enough to reverse the prevailing downtrend. That stubbornness has not gone unnoticed: with volatility running at 32 percent and the stock hovering just 1.0 percent below its 200-day moving average of 39.15 euros, technicians see a stock stuck in neutral — neither convincingly broken down nor ready to break out.
The Theranostics Bet
While the balance sheet mechanics grind on, the operational pipeline is gaining definition. The most intriguing thread involves Radiopharm Theranostics, the Australian partner with which Siemens Healthineers is collaborating on the production and distribution of RAD101, an imaging agent designed to detect brain metastases.
The clinical data so far are striking: Phase 2b results showed a 93 percent concordance between conventional MRI imaging and PET imaging using RAD101. The two companies have scheduled a pivotal meeting with the US Food and Drug Administration for October 1 to finalize the design of the Phase 3 study. Siemens Healthineers, which already holds FDA "Fast Track" designation for the project, would be responsible for manufacturing and distributing the 18F-labeled doses across the United States.
Success here would cement the company's role as an indispensable infrastructure partner in the emerging field of theranostics — a high-margin growth area that could offset some of the sluggishness in the core diagnostics business. Failure, or even delay, would leave the hoped-for catalyst unrealized and could expose the stock to a retest of its 52-week low of 32.84 euros.
Siemens Healthineers at a turning point? This analysis reveals what investors need to know now.
A Separate Track: Clinical Partnerships
The Radiopharm collaboration is not the only alliance in motion. Late July brought news of a partnership with Vanderbilt University valued at 87 million US dollars, aimed at deepening clinical cooperation. Such agreements provide incremental revenue streams while the company simultaneously works through the mechanics of divesting Diagnostics — a reminder that the restructuring and the day-to-day operations are proceeding on parallel tracks.
What to Watch
For investors, the calculus is straightforward but not simple. The resolved tax question removes a major overhang from the spin-off timeline, and the buyback program offers a floor of sorts. The lowered growth guidance, however, tempers enthusiasm, and the extended horizon for the Diagnostics sale — up to two years — means the payoff from the restructuring will not arrive quickly.
The near-term calendar offers two distinct moments of truth. The first comes in early September, when management appears at the Jefferies Swiss Healthcare Summit in Zurich. The second, more consequential, arrives on October 1 with the FDA meeting on RAD101 — a date that could determine whether the theranostics narrative gains real momentum or fades into the background. Fourth-quarter results follow on November 5, providing the next full financial picture.
Until then, the stock sits in a waiting zone defined by the 200-day line above and the 38-euro support level below — a range that reflects a market still deciding whether the sum of tax clarity, buybacks, and clinical ambition outweighs the weight of a lowered growth trajectory and an unfinished corporate transformation.
Ad
Siemens Healthineers Stock: New Analysis - 18 August
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
